Schedule of Number and Weighted Average Exercise Prices of Option (Details) - Chemomab Therapeutics Ltd [Member] - $ / shares |
6 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
Jun. 30, 2026 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Weighted average exercise price, Outstanding at the beginning | $ 0.14 | $ 0.15 | $ 0.16 | $ 0.33 | |
| Number of options, Outstanding at the beginning | 31,492,720 | 32,050,300 | 29,873,100 | 35,191,540 | |
| Weighted average remaining contractual life, Outstanding | 6 years 1 month 20 days | 6 years 8 months 15 days | 7 years 4 months 2 days | 5 years 11 months 26 days | 7 years 5 months 1 day |
| Weighted average exercise price, Exercise | $ 0.03 | ||||
| Number of options, Exercised | (449,920) | ||||
| Weighted average exercise price, Forfeited | $ 0.17 | $ 0.11 | $ 0.19 | $ 0.39 | |
| Number of options, Forfeited | (1,418,880) | (4,869,540) | (667,820) | (20,373,620) | |
| Weighted average exercise price, Granted | $ 0.03 | $ 0.06 | $ 0.03 | $ 0.07 | |
| Number of options, Granted | 1,930,960 | 4,761,880 | 2,845,020 | 15,055,180 | |
| Weighted average remaining contractual life, Granted | 9 years 9 months 14 days | 9 years 3 months 18 days | 8 years 6 months 21 days | 5 years 10 months 9 days | |
| Weighted average exercise price, Outstanding at ending | $ 0.13 | $ 0.14 | $ 0.15 | $ 0.16 | $ 0.33 |
| Number of options, Outstanding at the ending | 32,004,800 | 31,492,720 | 32,050,300 | 29,873,100 | 35,191,540 |
| X | ||||||||||
- Definition Stock issued during period shares option. No definition available.
|
| X | ||||||||||
- Definition Stock issued during period shares option. No definition available.
|
| X | ||||||||||
- Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Gross number of share options (or share units) granted during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of options outstanding, including both vested and non-vested options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|